Posted by This study aimed to magnetize β-cyclodextrin (β-CD) to serve as a nanocarrier for sitagliptin (Sita) in targeted drug delivery applications. To achieve this, β-CD was modified with carboxymethyl groups and magnetized with paramagnetic iron oxide, then functionalized using carbodiimide. Subsequently, Sita was loaded onto the Fe3O4-modified-Carboxymethyl-β-cyclodextrin (FeCMCD). The successful synthesis of magnetic drug-loaded nanoparticles (FeCMCD/Sita) was confirmed through comprehensive characterization using XRD, TEM, VSM, TGA, DLS, BET, and FT-IR analysis. The results indicated that the prepared FeCMCD/Sita had an average size of 50 nm with a spherical morphology, as revealed by DLS data showing a size distribution of less than 100 nm. The saturated magnetization of the final product was calculated to be 42 emu/g, with a loading efficiency of approximately 72 % for Sita. Additionally, the magnetized nanocarrier exhibited pH-responsive behavior in drug release studies, with the highest release observed at 90 % under pH 8 after 72 h. Furthermore, cytotoxicity evaluation of FeCMCD/Sita was performed through MTT analysis on Human umbilical vein endothelial cells (HUVEC), showing no significant toxicity. These findings demonstrated that FeCMCD/Sita is a promising candidate for targeted diabetic therapy.
Yang Hanqi, Reza Allahyari, Mehrdad Hadadian, Behnam Mahdavi, Mehdi Baghayeri (2025) Development of a magnetic Carboxymethyl-β-Cyclodextrin nanocarrier for targeted sitagliptin delivery. Journal of Molecular Liquids 127872. https://doi.org/10.1016/j.molliq.2025.127872